ASH 2018 Annual Meeting Highlights in Multiple Myeloma

Faith Davies, MD, MBBCh, MRCP, FRCPath KCRD Vs. CTD/CRD Induction Therapy Prior to ASCT Run Time: 04:22 Begin

Meletios A. Dimopoulos, MD Ixazomib Prolongs PFS Following ASCT in Patients with NDMM: Phase 3 Tourmaline-MM3 Trial Run Time: 04:52 Begin

Meletios A. Dimopoulos, MD Once vs. Twice Weekly Carfilzomib Dosing in Patients with RRMM: Phase 3 A.R.R.O.W Study Run Time: 02:21 Begin

Meletios A. Dimopoulos, MD Isatuximab as a Single Agent and in combination with Dexamethasone in RRMM Run Time: 02:57 Begin

Shaji K. Kumar, MD Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with RRMM Run Time: 04:15 Begin

Shaji K. Kumar, MD Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with NDMM Run Time: 04:37 Begin

María-Victoria Mateos, MD, PhD Carfilzomib in RRMM Patients with Early or Late Relapse Following Prior Therapy Run Time: 06:15 Begin

María-Victoria Mateos, MD, PhD Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone Run Time: 06:32 Begin

Philip L. McCarthy, MD Anti-BCMA CAR T-cell Therapy for RRMM Run Time: 04:00 Begin

Noopur Raje, MD Initial Results from a Phase 1 Clinical Study of bb21217 Run Time: 03:59 Begin

Noopur Raje, MD Updated Analysis of LCAR-B38M in Patients with RRMM Run Time: 03:26 Begin

Dan T. Vogl, MD, MSCE Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM Run Time: 06:36 Begin